Cord Blood Unit Access and Selection: 2010 and Beyond: Best Practices and Emerging Trends in Cord Blood Unit Selection

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Boo, Michael ^a   Ballen, Karen ^b   Maiers, Martin ^a  

^a NATIONAL MARROW DONOR PROGRAM   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cord blood; Matching algorithm; Regulation

Indexed keywords

ALLOTRANSPLANTATION; ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FACILITY; HEALTH CARE POLICY; HLA MATCHING; HUMAN; PATIENT SELECTION; PEDIATRICS; PRACTICE GUIDELINE; REGISTER; UMBILICAL CORD BLOOD UNIT;

EID: 78650665013     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.010     Document Type: Article

References (41)

1. Guidance for Industry. Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications, October 20, 2009.
2. Draft Guidance for Industry and FDA Staff. Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications. October 20, 2009.
3. A Proposed Approach to Regulation of Cellular and Tissue-Based Products (62 FR 9721, March 4, 1997).
4. 21 CFR 1271.
5. Human Cells, Tissues, and Cellular and Tissue-Based Products; Establishment Registration and Listing (66 FR 5447), January 19, 2001.
6. May 25, 2004. Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (69 FR 29786).
7. November 24, 2004. Current Good Tissue Practice for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products; Inspection and Enforcement (69 FR 68612).
8. 1 CFR Part 601.
9. Guidance for Industry, p. 2.
10. Section 361 of the Public Health Service Act, (42 U.S.C. 264).
11. 21 CFR Parts 201, and 610.
12. 21 CFR Part 202.
13. 21 CFR Parts 210 and 211.
14. 21 CFR Part 600.
15. 21 CFR 312.8.
16. Kurtz berg J., Laughlin M., Graham M.L., et al. Placental blood as a source of hematopoietic stem cell for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
17. Wagner JE, Rosenthal J, Sweetman R, et al. Successful HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft versus host disease. Blood. 1006;88:795-802.
18. Rocha V., Cornish J., Severs E.L., et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001, 97:2962-2971.
19. Locatelli F., Rocha V., Reed W., et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Euro cord-Cord Blood Transplant Group. Blood 1999, 93:3662-3671.
20. Rubinstein P., Stevens C.E. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Bailers Best Pact Rees Clint Hematol 2000, 13:564-584.
21. Gluckman E., Rocha V., Acres W., et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004, 32:397-407.
22. Barker J., Scaradavou A., Stevens C., et al. Analysis of 608 umbilical cord blood transplants: HLA-match is a critical determinant of transplant-related mortality in the post engraftment period even in the absence of acute graft-versus-host disease. Blood 2005, 106. abstract 303.
23. Eapen M., Rubinstein P., Zhang M.J. Comparison of outcomes after transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia. Lancet 2007, 369:1947-1954.
24. Prasad V.K., Maniacal A., Parikh S.H., et al. Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 2008, 112:2979-2989.
25. Wall D.A., Chan K.W. Selection of cord blood unit for transplantation. Bone Marrow Transplant 2008, 42:1-7.
26. Solomon M., Wofford J., Johnson C., et al. Factors influencing cord blood viability assessment before cryopreservation. Transfusion 2010, 50:820-830.
27. Rodriguez L., Garcia J., Querol S. Predictive utility of the attached segment in the quality control of a cord blood graft. Biol Blood Marrow Transplant 2005, 111:247-251.
28. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor hematopoietic stem-cell transplantation in adults with acute leukemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
29. Barker J.N., Scaradavou A., Stevens C. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010, 1115:1843-1849.
30. Takanashi M., Fujiwara K., Tanaka H., et al. The impact of HLA antibodies on engraftment of unrelated cord blood transplants. Transfusion 2008, 48:791-793.
31. van Rood J.J., Stevens C.E., Smits J., et al. Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematologic malignancies. Proc Natl Acad Sci USA 2009, 106:19952-19957.
32. Rocha V., Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose, and other graft-and transplantation-related factors. Br J Hematol 2009, 147:262-274.
33. Ballen K.K., Spitzer T.R., Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007, 13:82-89.
34. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
35. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
36. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2010, [Epub ahead of print].
37. Delaney M., Cutler S., Haspel R.L., et al. High-resolution HLA matching in double umbilical cord blood reduced intensity transplantation in adults. Transfusion 2009, 49:995-1002.
38. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
39. Brunstein C.G., Wagner J.E., Weisdorf D.J., et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood 2009, 113:5628-5634.
40. Mori M.P., Beatty P.G., Graves M., Boucher K.M., Milford E.L. HLA gene and haplotype frequencies in the north american popluation. Transplantation 1997, 64:1017-1027.
41. Mori M., Graves M., Milford E.L., Beatty P.G. Computer program to predict likelihood of finding an HLA-matched donor: methodology, validation, and application. Biol Blood Marrow Transplant 1996, 2:134-144.